PCM
GYRE icon

Polymer Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Polymer Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.6K Buy
+11,780
New +$80.3K 0.01% 592

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Polymer Capital Management's GYRE Position: Q2 2026 in Review

Polymer Capital Management opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 11,780 shares worth $77.6K. The stake represents 0.01% of the portfolio and ranks #592 among its holdings.

60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Polymer Capital Management held 11,780 shares of Gyre Therapeutics worth $77.6K as of Q2 2026.
  • Gyre Therapeutics was a new Polymer Capital Management position in Q2 2026.
  • Gyre Therapeutics made up 0.01% of Polymer Capital Management's portfolio in Q2 2026, its #592 holding.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.